US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TNF Pharmaceuticals, Inc.

0.1395

-0.0003-0.21%

Post-market: 0.14000.0005+0.36%19:56 EDT

Volume:1.50M

Turnover:210.83K

Market Cap:1.98M

PE:-0.01

High:0.1477

Open:0.1353

Low:0.1353

Close:0.1398

Loading ...

Overview Company News Filings

TNF Pharmaceuticals Inc. Held Annual Stockholders Meeting

TNF Pharmaceuticals Q1 EPS $(0.36) Up From $(5.14) YoY

TNF Pharmaceuticals Lowers Shareholder Vote Requirement in Bylaw Amendment

Tnf Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating Tnf-Driven Inflammation in Patients Receiving Glp-1 Agonists

THOMSON REUTERS

TNF Pharmaceuticals, Renova Health partner using AI for drug development

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

TNF Pharmaceuticals presents isomyosamine data

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

Tnf Pharmaceuticals Initiates Phase 2B Clinical Trial of First Oral Tnf-Alpha Inhibitor

THOMSON REUTERS

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1s

Tnf Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During Glp-1 Weight Loss Treatment

THOMSON REUTERS

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals isomyosamine trial demonstrates safety

Tnf Pharmaceuticals Inc - to Begin Phase 2B Study in Sarcopenia

THOMSON REUTERS

Tnf Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

THOMSON REUTERS

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TNFA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TNFA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TNFA\",,,,,undefined,":{"symbol":"TNFA","market":"US","secType":"STK","nameCN":"TNF Pharmaceuticals, Inc.","latestPrice":0.1395,"timestamp":1750449600000,"preClose":0.1398,"halted":0,"volume":1496260,"hourTrading":{"tag":"盘后","latestPrice":0.14,"preClose":0.1395,"latestTime":"19:56 EDT","volume":133319,"amount":18566.1913,"timestamp":1750463774914},"delay":0,"floatShares":14166000,"shares":14184088,"eps":-11.14535,"marketStatus":"Market Closed","change":-0.0003,"latestTime":"06-20 16:00:00 EDT","open":0.1353,"high":0.1477,"low":0.1353,"amount":210831.622532,"amplitude":0.088698,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-11.14535,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"listingDate":1390453200000,"exchange":"NASDAQ","adjPreClose":0.1398,"preHourTrading":{"tag":"盘前","latestPrice":0.1378,"preClose":0.1398,"latestTime":"09:23 EDT","volume":5921,"amount":815.911668,"timestamp":1750425793780},"postHourTrading":{"tag":"盘后","latestPrice":0.14,"preClose":0.1395,"latestTime":"19:56 EDT","volume":133319,"amount":18566.1913,"timestamp":1750463774914},"volumeRatio":0.4730966313529645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TNFA\",,,,,undefined,":{"symbol":"TNFA","floatShares":14166000,"roa":"-31.36%","roe":"-121.95%","lyrEps":-11.14535,"volumeRatio":0.4730966313529645,"shares":14184088,"dividePrice":0,"high":0.1477,"amplitude":0.088698,"preClose":0.1398,"low":0.1353,"week52Low":0.13,"pbRate":"0.23","week52High":2.16,"institutionHeld":0,"latestPrice":0.1395,"eps":-11.14535,"divideRate":0,"volume":1496260,"delay":0,"ttmEps":-11.14535,"open":0.1353,"prevYearClose":1.15,"prevWeekClose":0.137,"prevMonthClose":0.1604,"prevQuarterClose":0.35,"fiveDayClose":0.1532,"twentyDayClose":0.1538,"sixtyDayClose":0.3556},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TNFA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541893099","title":"TNF Pharmaceuticals Inc. Held Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541893099","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541893099?lang=en_us&edition=fundamental","pubTime":"2025-06-07 05:01","pubTimestamp":1749243681,"startTime":"0","endTime":"0","summary":"TNF Pharmaceuticals Inc. held its 2025 annual meeting of stockholders on June 3, 2025. During the meeting, stockholders approved a proposal to amend the Certificate of Incorporation to increase the number of authorized shares of common stock from 250,000,000 to 1,250,000,000. Additionally, stockholders approved a Preferred Stock Proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL5MR4gd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNFA","BK4007"],"gpt_icon":0},{"id":"2535213806","title":"TNF Pharmaceuticals Q1 EPS $(0.36) Up From $(5.14) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535213806","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535213806?lang=en_us&edition=fundamental","pubTime":"2025-05-16 05:55","pubTimestamp":1747346148,"startTime":"0","endTime":"0","summary":"TNF Pharmaceuticals (NASDAQ:TNFA) reported quarterly losses of $(0.36) per share. This is a 93 percent increase over losses of $(5.14) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45456676/tnf-pharmaceuticals-q1-eps-0-36-up-from-5-14-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNFA"],"gpt_icon":0},{"id":"2534466684","title":"TNF Pharmaceuticals Lowers Shareholder Vote Requirement in Bylaw Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2534466684","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534466684?lang=en_us&edition=fundamental","pubTime":"2025-05-10 05:29","pubTimestamp":1746826143,"startTime":"0","endTime":"0","summary":"TNF Pharmaceuticals Inc. announced an amendment to its bylaws, effective May 9, 2025. The amendment modifies Article II, Section 2.09, changing the required stockholder vote for matters other than the election of directors. The new rule requires a majority of votes cast by stockholders present or represented by proxy, excluding abstentions and broker non-votes, for approval. This change also applies to class votes, where applicable.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 09, 2025, and is solely responsibl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nNDL18D1d7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNFA","BK4007"],"gpt_icon":0},{"id":"2533138073","title":"Tnf Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating Tnf-Driven Inflammation in Patients Receiving Glp-1 Agonists","url":"https://stock-news.laohu8.com/highlight/detail?id=2533138073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533138073?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:20","pubTimestamp":1746710400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA24TNG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TNFA"],"gpt_icon":0},{"id":"2529854285","title":"TNF Pharmaceuticals, Renova Health partner using AI for drug development","url":"https://stock-news.laohu8.com/highlight/detail?id=2529854285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529854285?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:36","pubTimestamp":1745328993,"startTime":"0","endTime":"0","summary":"TNF Pharmaceuticals (TNFA) announced a collaboration with Renova Health using AI and machine learning technologies to identify high-risk patient gr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tnf-pharmaceuticals-renova-health-partner-using-ai-for-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tnf-pharmaceuticals-renova-health-partner-using-ai-for-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNFA","BK4007"],"gpt_icon":0},{"id":"2529583339","title":"TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2529583339","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529583339?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:15","pubTimestamp":1745327700,"startTime":"0","endTime":"0","summary":"Machine learning technology used to identify patients for studies of muscle mass preservation during GLP-1 treatment. \"We are thrilled to collaborate with TNF Pharmaceuticals to advance precision medicine through our cutting-edge NLP, LLM, and AI platform,\" said David Jacobs, CEO of Renova Health. \"Our technology transcends traditional big data analytics by creating highly specific patient personas, identifying optimal cohorts for isomyosamine based on underlying conditions, acute events, and medication profiles. Furthermore, our platform uncovers the nuanced impact of individual physician practices—such as varying diagnosis codes for GLP-1 prescriptions, like BMI versus diabetes—which can significantly influence cohort selection and study outcomes. This unparalleled precision enables TNF Pharmaceuticals to target patients who stand to benefit most, accelerating study timelines and enhancing therapeutic impact.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-renova-health-utilize-131500390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AAQC","BK4113","BK4557","ACB","BK4007","CBD","TNFA"],"gpt_icon":0},{"id":"2527499852","title":"TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499852","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499852?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:15","pubTimestamp":1744809300,"startTime":"0","endTime":"0","summary":"Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture. Drug shown to decrease biomarkers associated with TNF-alpha activation in elderly patients with sarcopenia. BALTIMORE, April 16, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that a platform presentation of an abstract titled \"Isomyosamine for the Treatment of Sarcopenia in Older Adults\" was delivered by Mitchell Glass, M.D., President and Chief Medical Officer of TNF, at the British Geriatrics Society  Spring Meeting 2025, held April 9-11, 2025, in Belfast, Ireland and online.During his presentation, Dr. Glass spoke about the Company’s small-molecule TNF-alpha  inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines associated with sarcopenia. In response to a question, he emphasized the Company's ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-delivers-platform-presentation-131500476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TNFA","BK4113","BGB","ACB","BK4007","BK4557","CBD"],"gpt_icon":0},{"id":"2520222595","title":"TNF Pharmaceuticals presents isomyosamine data","url":"https://stock-news.laohu8.com/highlight/detail?id=2520222595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520222595?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:25","pubTimestamp":1742217945,"startTime":"0","endTime":"0","summary":"TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was pre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tnf-pharmaceuticals-presents-isomyosamine-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tnf-pharmaceuticals-presents-isomyosamine-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNFA","BK4007"],"gpt_icon":0},{"id":"2520352170","title":"TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2520352170","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520352170?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:15","pubTimestamp":1742217300,"startTime":"0","endTime":"0","summary":"Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss. BALTIMORE, March 17, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced that data from the Phase 2a clinical trial of its oral TNF-alpha  inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International Conference on Frailty and Sarcopenia Research  held March 12-14, 2025, in Toulouse, France.The presentation included positive Phase 2a clinical data showing decreases of biomarkers associated with TNF-α activation in elderly patients with sarcopenia. The Company’s recently initiated Phase 2b clinical trial will further evaluate isomyosamine as a treatment for chronic inflammation associated with muscle loss  in patients who have undergone hip or femur fracture re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-delivers-podium-presentation-131500702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACB","CBD","TNFA","BK4113","BK4557","BK4007"],"gpt_icon":0},{"id":"2517191086","title":"TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517191086","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517191086?lang=en_us&edition=fundamental","pubTime":"2025-03-05 22:00","pubTimestamp":1741183200,"startTime":"0","endTime":"0","summary":"Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss. Investors invited to submit questions prior to the event. BALTIMORE, March 05, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company’s lead candidate isomyosamine, a novel oral TNF-alpha  inhibitor drug shown to positively impact conditions related to immunometabolic dysregulation.A Phase 2b clinical trial is currently underway to evaluate isomyosamine as a treatment for chronic inflammation associated with muscle loss  in patients who have undergone hip or femur fracture repair surge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-host-investor-conference-140000460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACB","BK4181","BK4588","BK4585","BK4113","HST","BK4007","CBD","TNFA","BK4557","BK4218"],"gpt_icon":0},{"id":"2514092729","title":"Tnf Pharmaceuticals Initiates Phase 2B Clinical Trial of First Oral Tnf-Alpha Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2514092729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514092729?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:20","pubTimestamp":1740493200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA9HYYZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNFA","BK4007"],"gpt_icon":0},{"id":"2514609758","title":"TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2514609758","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514609758?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:20","pubTimestamp":1740493200,"startTime":"0","endTime":"0","summary":"Fully funded multi-center study initiated at University of Florida to further explore efficacy of isomyosamine for preventing progressive muscle loss and frailty. Study builds on positive results achieved in earlier Phase 2a trial. TNF-alpha inhibitor market estimated at $40+ billion with no FDA-approved oral treatments. \"The initiation of our Phase 2b isomyosamine trial marks an important milestone in our mission to develop a novel science for immuno-metabolic regulation and increased longevity,\" said Mitchell Glass, M.D., President and Chief Medical Officer of TNF. \"A deeper exploration of isomyosamine’s efficacy will be studied in patients with acute post-surgical inflammation and complications from hip or femur fractures. In addition to further functional decline, these patients face a higher likelihood of complications that can compromise or delay recovery and are associated with higher healthcare costs.\". Isomyosamine is an oral, next-generation TNF-α inhibitor with the potential","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-initiates-phase-2b-142000584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CBD","BK4159","BK4007","CAGR","BK4557","TNFA","BK4113","ACB"],"gpt_icon":0},{"id":"2507963109","title":"TNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1s","url":"https://stock-news.laohu8.com/highlight/detail?id=2507963109","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507963109?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:30","pubTimestamp":1738161050,"startTime":"0","endTime":"0","summary":"TNF Pharmaceuticals (TNFA), announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha TNF...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tnf-pharmaceuticals-to-study-tnf-alpha-in-patients-taking-glp-1s?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tnf-pharmaceuticals-to-study-tnf-alpha-in-patients-taking-glp-1s?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNFA","BK4144","BK4007","BK4590","GLP"],"gpt_icon":0},{"id":"2507027636","title":"Tnf Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During Glp-1 Weight Loss Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2507027636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507027636?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:15","pubTimestamp":1738160101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nTUABPLBC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TNFA"],"gpt_icon":0},{"id":"2507631281","title":"TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2507631281","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507631281?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:15","pubTimestamp":1738160100,"startTime":"0","endTime":"0","summary":"Series of studies to observe signals of inflammation and TNF-alpha levels in patients taking GLP-1s including Wegovy or Ozempic. Lean body mass accounts for up to 40% of weight loss from GLP-1 treatments. BALTIMORE, January 29, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha  inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management.The first study examines TNF-α levels in patients receiving the GLP-1 agonist Wegovy or Ozempic who show signs of increased inflammation associated with sarcopenia, which is the progressive loss of muscle mass. Isomyosamine targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia.Isomyosamine is a novel plant alkaloid small mol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-launches-study-series-141500590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","GLP","TNFA","BK4159","CBD","BK4007","BK4113","CAGR","BK4557","ACB","BK4144","CDC"],"gpt_icon":0},{"id":"2503364272","title":"TNF Pharmaceuticals isomyosamine trial demonstrates safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2503364272","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503364272?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:25","pubTimestamp":1736951153,"startTime":"0","endTime":"0","summary":"TNF Pharmaceuticals (TNFA) announced that it has achieved a safety data milestone supporting expanded and longer-term clinical studies of its TNF-a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tnf-pharmaceuticals-isomyosamine-trial-demonstrates-safety?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tnf-pharmaceuticals-isomyosamine-trial-demonstrates-safety?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNFA","BK4007"],"gpt_icon":0},{"id":"2503764464","title":"Tnf Pharmaceuticals Inc - to Begin Phase 2B Study in Sarcopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2503764464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503764464?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:15","pubTimestamp":1736950500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUAQXHMH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNFA","BK4007"],"gpt_icon":0},{"id":"2503644589","title":"Tnf Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2503644589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503644589?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:15","pubTimestamp":1736950500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUAQXHMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNFA","BK4007"],"gpt_icon":0},{"id":"2503164293","title":"TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2503164293","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503164293?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:15","pubTimestamp":1736950500,"startTime":"0","endTime":"0","summary":"Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty. Transformative potential for novel TNF-alpha inhibitor drug:Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market. BALTIMORE, January 15, 2025----TNF Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha  inhibitor drug, isomyosamine, in multiple indications.\"Positive data from this milestone study confirms isomyosamine’s historically strong safety profile and enables us to extend the duration of future clinical trials,\" said Mitchell Glass, M.D., President and Chief Medical Officer of TNFA. \"We believe we are fully equipped to advance our comprehensive isomyosamine platform in a longer-term clinical trial in sarcopeni","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnf-pharmaceuticals-announces-positive-clinical-141500016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4159","ACB","CAGR","CDC","BK4113","BK4007","CBD","TNFA","BK4557"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TNFA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TNFA","defaultRemindTime":1708007400000,"type":"split","dateTimestamp":1707973200000,"forFactor":30,"toFactor":1,"ratio":30},{"market":"US","date":"2023-11-14","symbol":"TNFA","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2023-08-14","symbol":"TNFA","fiscalQuarterEnding":"2023/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1691985600000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2023-05-15","symbol":"TNFA","fiscalQuarterEnding":"2023/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1684123200000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2023-03-31","symbol":"TNFA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1680235200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TNFA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TNFA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TNFA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TNFA","date":"2025-06-20","current":-0.13504,"percent":0.525114,"low":-0.378087,"twenty":-0.208009,"median":-0.137469,"eighty":-0.067558,"high":-0.029287,"avg":-0.145426,"sd":0.078823,"marketCap":1982935},"quantilePoints":[{"date":"2024-08-02","current":-0.378087,"twenty":-0.378087,"median":-0.378087,"eighty":-0.378087,"marketCap":4646029},{"date":"2024-08-09","current":-0.347223,"twenty":-0.369792,"median":-0.352046,"eighty":-0.351081,"marketCap":4266761},{"date":"2024-08-16","current":-0.349152,"twenty":-0.354939,"median":-0.351081,"eighty":-0.347223,"marketCap":4290465},{"date":"2024-08-23","current":-0.270733,"twenty":-0.35301,"median":-0.347223,"eighty":-0.270733,"marketCap":4788254},{"date":"2024-08-30","current":-0.237226,"twenty":-0.351081,"median":-0.337578,"eighty":-0.25331,"marketCap":4195648},{"date":"2024-09-06","current":-0.229185,"twenty":-0.351081,"median":-0.270733,"eighty":-0.238299,"marketCap":4053423},{"date":"2024-09-13","current":-0.197608,"twenty":-0.349538,"median":-0.258,"eighty":-0.222848,"marketCap":3494951},{"date":"2024-09-20","current":-0.170213,"twenty":-0.347609,"median":-0.247949,"eighty":-0.207679,"marketCap":3010437},{"date":"2024-09-27","current":-0.223824,"twenty":-0.347223,"median":-0.237897,"eighty":-0.194005,"marketCap":3958606},{"date":"2024-10-04","current":-0.190317,"twenty":-0.347223,"median":-0.229185,"eighty":-0.193534,"marketCap":3366000},{"date":"2024-10-11","current":-0.20372,"twenty":-0.339507,"median":-0.223382,"eighty":-0.196954,"marketCap":3603042},{"date":"2024-10-18","current":-0.237226,"twenty":-0.337578,"median":-0.223824,"eighty":-0.200353,"marketCap":4195648},{"date":"2024-10-25","current":-0.238567,"twenty":-0.284102,"median":-0.224159,"eighty":-0.201865,"marketCap":4219352},{"date":"2024-10-31","current":-0.195263,"twenty":-0.270733,"median":-0.224159,"eighty":-0.201658,"marketCap":3453469},{"date":"2024-11-08","current":-0.18111,"twenty":-0.265104,"median":-0.222939,"eighty":-0.19273,"marketCap":3203152},{"date":"2024-11-15","current":-0.164772,"twenty":-0.25733,"median":-0.221479,"eighty":-0.179692,"marketCap":2914198},{"date":"2024-11-22","current":-0.158373,"twenty":-0.253846,"median":-0.218463,"eighty":-0.176915,"marketCap":3746891},{"date":"2024-11-29","current":-0.131589,"twenty":-0.251166,"median":-0.215796,"eighty":-0.174368,"marketCap":3113225},{"date":"2024-12-06","current":-0.14207,"twenty":-0.245268,"median":-0.208411,"eighty":-0.167533,"marketCap":3361181},{"date":"2024-12-13","current":-0.138576,"twenty":-0.240711,"median":-0.20506,"eighty":-0.163497,"marketCap":3278529},{"date":"2024-12-20","current":-0.171183,"twenty":-0.239371,"median":-0.202863,"eighty":-0.160563,"marketCap":4049948},{"date":"2024-12-27","current":-0.150221,"twenty":-0.238567,"median":-0.201555,"eighty":-0.157442,"marketCap":3554036},{"date":"2025-01-03","current":-0.133918,"twenty":-0.238567,"median":-0.196435,"eighty":-0.147892,"marketCap":3168327},{"date":"2025-01-10","current":-0.149057,"twenty":-0.237494,"median":-0.192327,"eighty":-0.14533,"marketCap":3526485},{"date":"2025-01-17","current":-0.138576,"twenty":-0.237226,"median":-0.182828,"eighty":-0.144166,"marketCap":3278529},{"date":"2025-01-24","current":-0.133918,"twenty":-0.236422,"median":-0.179756,"eighty":-0.14207,"marketCap":3168327},{"date":"2025-01-31","current":-0.103513,"twenty":-0.235886,"median":-0.178925,"eighty":-0.138576,"marketCap":2448979},{"date":"2025-02-07","current":-0.069766,"twenty":-0.232669,"median":-0.176915,"eighty":-0.137179,"marketCap":1650560},{"date":"2025-02-14","current":-0.066109,"twenty":-0.229721,"median":-0.174569,"eighty":-0.134617,"marketCap":1564051},{"date":"2025-02-21","current":-0.057282,"twenty":-0.228113,"median":-0.171765,"eighty":-0.133918,"marketCap":1355217},{"date":"2025-02-28","current":-0.050039,"twenty":-0.226236,"median":-0.168854,"eighty":-0.132356,"marketCap":1183852},{"date":"2025-03-07","current":-0.047395,"twenty":-0.225303,"median":-0.167533,"eighty":-0.127397,"marketCap":1121312},{"date":"2025-03-14","current":-0.040408,"twenty":-0.224502,"median":-0.164772,"eighty":-0.116749,"marketCap":956008},{"date":"2025-03-21","current":-0.042446,"twenty":-0.224226,"median":-0.162602,"eighty":-0.082729,"marketCap":1004221},{"date":"2025-03-28","current":-0.041806,"twenty":-0.223824,"median":-0.158373,"eighty":-0.066717,"marketCap":989069},{"date":"2025-04-04","current":-0.047058,"twenty":-0.22347,"median":-0.156627,"eighty":-0.062131,"marketCap":1113322},{"date":"2025-04-11","current":-0.029986,"twenty":-0.222757,"median":-0.149057,"eighty":-0.056381,"marketCap":709429},{"date":"2025-04-17","current":-0.106578,"twenty":-0.22235,"median":-0.147892,"eighty":-0.057471,"marketCap":2489584},{"date":"2025-04-25","current":-0.083284,"twenty":-0.22168,"median":-0.144981,"eighty":-0.058633,"marketCap":1945462},{"date":"2025-05-02","current":-0.087231,"twenty":-0.220875,"median":-0.143234,"eighty":-0.060552,"marketCap":2037669},{"date":"2025-05-09","current":-0.085279,"twenty":-0.219535,"median":-0.141487,"eighty":-0.061919,"marketCap":1992072},{"date":"2025-05-16","current":-0.085583,"twenty":-0.218195,"median":-0.138576,"eighty":-0.063258,"marketCap":1999165},{"date":"2025-05-23","current":-0.112408,"twenty":-0.216858,"median":-0.138576,"eighty":-0.065401,"marketCap":1650603},{"date":"2025-05-30","current":-0.114271,"twenty":-0.215796,"median":-0.137469,"eighty":-0.066109,"marketCap":1677961},{"date":"2025-06-06","current":-0.110131,"twenty":-0.214442,"median":-0.136247,"eighty":-0.066424,"marketCap":1617165},{"date":"2025-06-13","current":-0.147984,"twenty":-0.209081,"median":-0.137469,"eighty":-0.067157,"marketCap":2173002},{"date":"2025-06-20","current":-0.13504,"twenty":-0.208009,"median":-0.137469,"eighty":-0.067558,"marketCap":1982935}],"updateTime":1750567920273}}}